Molecular Partners Says Its COVID-19 Antiviral Still Effective Against Positions Mutated In OmicronBenzinga • 11/30/21
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In VitroGlobeNewsWire • 11/30/21
Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx ConferenceGlobeNewsWire • 11/24/21
See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?Benzinga • 11/16/21
Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19GlobeNewsWire • 11/16/21
Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology MomentumGlobeNewsWire • 10/28/21
Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2021 ISIRV-WHO ConferenceGlobeNewsWire • 10/20/21
Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021GlobeNewsWire • 08/26/21
Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2GlobeNewsWire • 07/08/21